Shares of Sarepta (SRPT), which have been in negative ground since the open after a third death following dosing with one of the company’s gene therapies was reported, have taken a further leg lower after the Commissioner of the FDA Marty Makary told Bloomberg that the regulator is “taking a hard look” at whether Sarepta’s Elevidys should stay on the market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- FDA head tells Bloomberg ‘taking hard look’ if Elevidys should stay on market
- Needham downgrades Sarepta after patient death, questions management credibility
- Sarepta downgraded to Hold from Buy at Needham
- Sarepta CEO says didn’t disclose patient death on Weds. call, ‘wasn’t salient’
- Another liver toxicity death adds to Sarepta concerns, says Morgan Stanley